Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Beam Therapeutics (BEAM) to $70 from $75 and keeps an Overweight rating on the shares. The firm thinks BEAM-302 dosing at 75 mg should solidify the efficacy profile with higher serum AAT levels. Wells also expects EHA SCD data in June to further support the best-in-class profile of BEAM-101.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
- Beam Therapeutics: Promising Growth Prospects and Strategic Advancements Support Buy Rating
- Beam Therapeutics price target lowered to $25 from $31 at Barclays
- Beam Therapeutics Reports Strong Q1 2025 Progress
- Beam Therapeutics reports Q1 EPS ($1.24), consensus ($1.17)